Healthcare Analysts discuss emerging therapies in chronic myeloid leukemia (CML), (relevant companies NVS, ENLV, TERN, TAK, BMY, PFE) on an Analyst/Industry conference call to be held on October 31.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Trump Trade: Trump administration prepares new probe into pharma prices
- Novartis announces expiration of HSR Act waiting period of Tourmaline Bio offer
- Novartis announces Cosentyx met primary endpoint in Phase III REPLENISH trial
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Novartis presents new Pluvicto data, showed improvement in rPFS